In WHO grade IV glioma groups, by adjusting to a lower threshold and re-conducting survival analysis, the results showed that the effect of survival time was significant, which proved that the high expression of PYGL was related to the worse prognosis of patients with WHO grade IV gliomas. Here, PYGL is linked to central nervous system cancer.